VALUE BASED PRICING: WHAT IS THE FUTURE FOR PATIENT ACCESS SCHEMES?

被引：1

作者：

Loveman, C. M. ^{[1
]}

Mallinson, M. ^{[1
]}

Areteou, T. ^{[1
]}

White, R. ^{[1
]}

机构：

[1] Double Helix Consulting, London, England

来源：

VALUE IN HEALTH | 2011年 / 14卷 / 03期

关键词：

D O I：

10.1016/j.jval.2011.02.170

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A30 / A30

页数：1

共 50 条

[1] IMPACT OF VALUE BASED PRICING ON FUTURE OF PATIENT ACCESS SCHEMES IN THE UK
Izmirlieva, M.
Walker, S.
Marinoni, G.
Ando, G.
VALUE IN HEALTH, 2012, 15 (07) : A313 - A313
[2] Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Towse, Adrian
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (03) : 360 - 366
[3] Value-Based Pricing and Patient Access for Specialty Drugs
Robinson, James C.
Howell, Scott
Pearson, Steven D.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (21): : 2169 - 2170
[4] WHAT IS THE IMPACT OF COMPARATIVE EFFECTIVENESS AND VALUE BASED PRICING ON A PRODUCT'S VALUE AND MARKET ACCESS?
Walker, R.
Ng-Haing, J.
Koruth, R.
Sparrowhawk, K.
VALUE IN HEALTH, 2011, 14 (03) : A22 - A22
[5] LITERATURE REVIEW ON PATIENT ACCESS SCHEMES, FLEXIBLE PRICING SCHEMES AND RISK SHARING AGREEMENTS FOR MEDICINES
Puig-Peiro, R.
Mestre-Ferrandiz, J.
Sussex, J.
Towse, A.
VALUE IN HEALTH, 2011, 14 (07) : A243 - A243
[6] VALUE-BASED PRICING IN THE UK AND POTENTIAL PATIENT ACCESS HURDLES TO INNOVATIVE DRUGS
Papadopoulou, K.
Grosvenor, A.
VALUE IN HEALTH, 2013, 16 (07) : A492 - A492
[7] NICE PATIENT ACCESS SCHEMES -A WHO, WHAT, WHY, WHEN AND HOW
Macaulay, R.
Jamali, E.
VALUE IN HEALTH, 2015, 18 (07) : A552 - A552
[8] WHAT IS THE GOAL OF VALUE-BASED PRICING, AND TO WHOM IS VALUE CREATED?
Vassoler, H.
VALUE IN HEALTH, 2023, 26 (12) : S138 - S139
[9] WHAT MUST CHANGE IF FUTURE EVIDENCE PRICING AND ACCESS CHALLENGES ARE TO BE SUCCESSFULLY OVERCOME?
Teale, C.
Tolley, R.
Morrison, S.
Ballantyne, A.
VALUE IN HEALTH, 2023, 26 (12) : S356 - S356
[10] SIMPLE DISCOUNTS TO SUBSCRIPTION-BASED MODELS: WHAT IS THE FUTURE OF MULTI-INDICATION ONCOLOGY PRICING AND ACCESS?
Doolub, N.
Meszarosova, D.
Poschen, C.
VALUE IN HEALTH, 2020, 23 : S465 - S465

← 1 2 3 4 5 →